- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02638168
Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD
September 16, 2019 updated by: Raman Baweja, Milton S. Hershey Medical Center
Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With Attention Deficit Hyperactivity Disorder: A Randomized Placebo-controlled Pilot Study
Over 10% of children in the United States are diagnosed with ADHD, and nearly half of these children have moderate to severe impairments in sleep, further exacerbating their already impaired academic, emotional and social functioning.
In children with ADHD, 34% of prescribed sleep medications are antipsychotics that can cause marked weight gain and metabolic changes; alternate medications have either been found to be ineffective, difficult to tolerate or are largely unstudied in youth.
Delayed sleep onset is strongly correlated with active symptoms of ADHD and Oppositional Defiant Disorder (ODD), suggesting that better control of disruptive behaviors could improve sleep patterns and this application will assess if the extension of the therapeutic effects of CNS stimulants into the early evening improves sleep onset.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
The goal of this application is to assess the impact of safer treatment option Methylphenidate (MPH) on sleep and behavior problems in children with Attention Deficit Hyperactivity Disorder (ADHD) and Behavioral Insomnia of Childhood (BIC).
ADHD affects over 11% of school-aged youth.
Similarly, pediatric sleep disorders occur in over a third of children and impact multiple domains of the child's functioning as well as that of their parents.
Children with ADHD are at an increased risk for sleep problems with a staggering comorbidity of up to 70%, while sleep deprivation worsens the already impaired social, emotional and academic functioning of children with ADHD.
Therefore, improving sleep may translate into enhanced functioning in multiple realms.
Delayed sleep onset latency (SOL) and bedtime resistance, the key component of the limit setting type of BIC, are particularly likely to occur in children with ADHD.
Medications are commonly used for both conditions with over 6% of all school-aged children in the United States prescribed medication for ADHD and 7% for sleep.
In children with ADHD, 34% of prescribed sleep medications are antipsychotics that can cause marked weight gain and metabolic changes.
Alternate medications for sleep have either been found to be ineffective, difficult to tolerate or are largely unstudied in youth.
MPH has an extensive database supporting their safety and efficacy.
Objective sleep studies of MPH have not found consistent results, with a few studies reporting delayed SOL and while others report improved quality of sleep.
Therefore, this proposal will evaluate the impact of extending MPH treatment into the early evening on sleep onset using a 3-week with-in subjects randomized trial of .3mg/kg of immediate release (IR) MPH dosed 3 hours before bedtime vs. placebo in 38 children with ADHD and chronically delayed SOL who have a history of prolonged stimulant usage.
The investigators will recruit 38 children ages 6-12 of any gender and racial/ethnic status with ADHD who have been treated with stable morning dose of extended release (ER) MPH for an extended time period (30 days or more) from the primary care and psychiatry clinics at Hershey Medical Center in Hershey, PA.
Recruitment will be split into three waves (13, 13, 12 participants).
Parents will be reminded to administer the blinded medication dose by text message each evening (or phone call by study staff) 3 hours prior to the desired bedtime.
Sleep onset will be measured by actigraphy and sleep log, with parents also reporting on level of ODD and ADHD symptoms in the evening.
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17036
- Milton S Hershey Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 12 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ages 6-12 (inclusive), and able to swallow capsule
- Children who have been treated with a stable morning dose of Extended Release Methylphenidate or twice daily dose of Immediate Release Methylphenidate for an extended period of time (30 days or longer).
- DSM V diagnosis of Attention Deficit Hyperactivity Disorder (ADHD): Diagnosis will be assessed on the NIMH Computerized Diagnostic Interview Schedule for Children (C-DISC), and parent and teacher rating scales.
- Children with any ADHD subtype meeting the above criteria will be eligible, although, it is expected that the majority will be of the combined subtype of ADHD given the associate between this subtype and ODD symptoms. A diagnosis of any of the two Behavioral Insomnia of Childhood (BIC) subtypes associated with delayed SOL (limit setting or combined type) will be required.
- Sex: male or female
- Fluent in written and spoken English.
Exclusion Criteria:
- Age < 6 years of age or >12 years of age.
- Children who have not had Methylphenidate (Extended Release) treatment for an extended period of time (30 days or longer).
- A diagnosis or suspicion of sleep-disordered breathing will be exclusionary as it is not expected to be impacted by Immediate Release Methylphenidate treatment.
- Current psychotropics other than Methylphenidate (Extended Release or Immediate Release Methylphenidate). Children prescribed alpha agonists for adjunctive control of ADHD in combination with a MPH product will be allowed to enroll as long as they meet all other entry criteria (i.e. sleep must remained impaired with use of alpha agonist).
- Regular use of other medications that impact sleep within the last 14 days (i.e.: sedating antihistamines, melatonin).
- Active medical/psychiatric conditions that impact sleep (i.e.: severe asthma, Autism Spectrum Disorder diagnosis, marked developmental delay, or mood/anxiety disorder).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Immediate Release Methylphenidate
With-in subjects trial.
Subjects will be randomized to 0.3 mg/kg of Immediate Release Methylphenidate versus placebo over 3-weeks duration
|
The medication assessment procedure will be a double-blind, within-subject evaluation of placebo and matching evening dose of IR MPH rounded to the nearest 2.5mg increment with a max IR MPH dose of 0.3mg/kg.
Expected evening dose range will be from 2.5mg to 20mg with most participants receiving between 5 to 15mg per evening dose.
Dose will be determined based on current dose of their morning extended release stimulant
Other Names:
|
Placebo Comparator: Placebo
inert placebo ingredient
|
inert placebo ingredient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep Onset Latency (SOL) as Reported on the Parent Completed Sleep Log
Time Frame: 3 weeks
|
Sleep onset latency is defines as duration of time in bed until sleep, as reported on the parent completed sleep log
|
3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep Onset Latency (SOL), Defined as Time in Bed Until Sleep by Actigraphy
Time Frame: 3 weeks
|
Sleep onset latency is defines as duration of time in bed until sleep actigraphy
|
3 weeks
|
Pittsburgh Side Effects Rating Scale
Time Frame: 3 weeks
|
Pittsburgh Side Effects Rating Scale to evaluate adverse reactions to Methylphenidate Higher scores mean a worse outcome (more side effects with medication) This scales has 13 items, which are reported as None (0), Mild (1), Moderate (2) and Severe (3) Total score is calculated by summiting all items.
Total Score Ranges (0-39)
|
3 weeks
|
Sleep Offset
Time Frame: 3 weeks
|
3 weeks
|
|
Total Sleep Time
Time Frame: 3 weeks
|
3 weeks
|
|
Wake After Sleep Onset (WASO)
Time Frame: 3 weeks
|
3 weeks
|
|
Sleep Efficiency
Time Frame: 3 weeks
|
3 weeks
|
|
Number of Wakings
Time Frame: 3 weeks
|
3 weeks
|
|
Length of Wakings
Time Frame: 3 weeks
|
3 weeks
|
|
Night to Night Variability (Weekends & Weekdays) - in Sleep Onset Latency Measured by Actigraphy
Time Frame: 3 weeks
|
We calculated Night to night variability by the difference between the mean sleep onset latency during the weekend days and the mean sleep onset latency during the weekdays.
|
3 weeks
|
Parent Rated 10-item IOWA
Time Frame: 3 weeks
|
Higher scores mean severe symptoms This scales has 10 items, which are reported as Not at all (0), just a little (1), pretty much (2) and very much (3) Total score is calculated by summiting all items.
Total Score Ranges (0-30)
|
3 weeks
|
Affective Reactivity Index (ARI)
Time Frame: 3 weeks
|
Higher scores mean a worse symptoms This scales has 7 items, which are reported as Not true (0), somewhat true (1) certainly true (2) Total score is calculated by summiting all items.
Total Score Ranges (0-14)
|
3 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Raman Baweja, M.D., M.S., Milton S. Hershey Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (Actual)
June 1, 2018
Study Completion (Actual)
June 1, 2018
Study Registration Dates
First Submitted
December 15, 2015
First Submitted That Met QC Criteria
December 18, 2015
First Posted (Estimate)
December 23, 2015
Study Record Updates
Last Update Posted (Actual)
September 17, 2019
Last Update Submitted That Met QC Criteria
September 16, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Methylphenidate
Other Study ID Numbers
- STUDY00003056
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Behavioral Insomnia of Childhood
-
Sungshin Women's UniversityNational Research Foundation of KoreaRecruitingBehavioral Insomnia of ChildhoodKorea, Republic of
-
Marmara UniversityNot yet recruitingInsomnia | Behavioral Insomnia of Childhood
-
IWK Health CentreRecruiting
-
German Research FoundationCompletedBehavior Problem of Childhood and AdolescenceGermany
-
University Hospital, MontpellierCompletedBehavioral Disorders | Emotional Disorder of ChildhoodFrance
-
NYU Langone HealthNational Institute of Mental Health (NIMH); U.S. Department of EducationCompletedBehavior Problems of Childhood and AdolescenceUnited States
-
Göteborg UniversityCompletedBehavior Problem of Childhood and Adolescence
-
Mental Health Services in the Capital Region, DenmarkFrederiksberg University Hospital; The Danish Mental Health Foundation; Defactum...CompletedDepressive Symptoms | Mental Health Disorder | Emotional Problem | Anxiety Disorder of Childhood | Behavior Problem of Childhood and AdolescenceDenmark
-
Roxane LaboratoriesCompletedShort Term Treatment of InsomniaUnited States
-
Memorial Sloan Kettering Cancer CenterSohn Conference FoundationActive, not recruitingSurvivors of Childhood CancerUnited States
Clinical Trials on Immediate Release Methylphenidate
-
The University of Texas Health Science Center,...National Institute of Mental Health (NIMH)CompletedAutism | Attention Deficit Disorder With HyperactivityUnited States
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompleted
-
GlaxoSmithKlineQuotient ClinicalCompletedAutoimmune DiseasesUnited Kingdom
-
GlaxoSmithKlineQuotient SciencesCompletedAutoimmune DiseasesUnited Kingdom
-
Heptares Therapeutics LimitedQuotient ClinicalCompletedAlzheimer's DiseaseUnited Kingdom
-
Prof. HussTerminated
-
Massachusetts General HospitalMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Completed
-
PfizerCompleted
-
PfizerCompletedHealthy ParticipantsBelgium
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2 | Type 2 Diabetes MellitusUnited States